Literature DB >> 34532133

Urokinase plasminogen activator predicts poor prognosis in hepatocellular carcinoma.

Fei-Yu Niu1, Chuan Jin1, Lei Ma1, Yan-Xia Shi1, Xiao-Shan Li1, Peng Jiang1, Sha Gao1, Jin-Rong Lin1, Ye Song1.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and its prognosis remains dismal. Hence, it is important to identify the diagnostic and prognostic biomarkers for HCC. Urokinase plasminogen activator (uPA), an extracellular matrix (ECM)-degrading protease, plays a pivotal role in the invasion and metastasis of HCC.
METHODS: To confirm the clinical significance of uPA in HCC, we explored uPA expression in HCC in The Cancer Genome Atlas (TCGA) database. The expression level of uPA was further verified by quantitative reverse transcription polymerized chain reaction (qRT-PCR) in 133 pairs of primary HCC samples. A survival analysis was conducted with the Kaplan-Meier method in the HCC samples and TCGA database.
RESULTS: Our results showed that uPA was overexpressed in HCC and was significantly associated with HCC tumor size (P=0.015), differentiation grade (P=0.028), and absence of tumor encapsulation (P=0.010). Patients with high uPA expression levels had a poor outcome (P=0.026). TCGA database analysis was also consistent with our experimental results.
CONCLUSIONS: In conclusion, our findings revealed that uPA was overexpressed in HCC and was related to HCC malignant features including tumor size, differentiation grade and absence of tumor encapsulation. High uPA expression had a shorter survival time. It is a potential prognostic biomarker of HCC. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma (HCC); prognosis; urokinase plasminogen activator (uPA)

Year:  2021        PMID: 34532133      PMCID: PMC8421907          DOI: 10.21037/jgo-21-343

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  40 in total

1.  The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis.

Authors:  Helle Pappot; Anders N Pedersen; Nils Brünner; Ib J Christensen
Journal:  Lung Cancer       Date:  2005-12-01       Impact factor: 5.705

2.  Urinary-type plasminogen activator receptor/alpha 3 beta 1 integrin signaling, altered gene expression, and oral tumor progression.

Authors:  Supurna Ghosh; Jennifer Koblinski; Jeffrey Johnson; Yueying Liu; Aaron Ericsson; J Wade Davis; Zonggao Shi; Matthew J Ravosa; Susan Crawford; Shellaine Frazier; M Sharon Stack
Journal:  Mol Cancer Res       Date:  2010-02-09       Impact factor: 5.852

3.  Expression of E-cadherin and uPA and their association with the prognosis of pancreatic cancer.

Authors:  Sang Joon Shin; Kyeong Ok Kim; Min Kyoung Kim; Kyung Hee Lee; Myung Soo Hyun; Keuk Jun Kim; Joon Hyuk Choi; Hong Seok Song
Journal:  Jpn J Clin Oncol       Date:  2005-06-03       Impact factor: 3.019

4.  Assessment of the correlation between serum prolidase and alpha-fetoprotein levels in patients with hepatocellular carcinoma.

Authors:  Sevil Uygun Ilikhan; Muammer Bilici; Hatice Sahin; Ayşe Semra Demir Akca; Murat Can; Ibrahim Ilker Oz; Berrak Guven; M Cagatay Buyukuysal; Yucel Ustundag
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

Review 5.  The plasminogen activation system in tumor growth, invasion, and metastasis.

Authors:  P A Andreasen; R Egelund; H H Petersen
Journal:  Cell Mol Life Sci       Date:  2000-01-20       Impact factor: 9.261

Review 6.  Involvement of urokinase-type plasminogen activator system in cancer: an overview.

Authors:  Ahmed H Mekkawy; Mohammad H Pourgholami; David L Morris
Journal:  Med Res Rev       Date:  2014-02-18       Impact factor: 12.944

Review 7.  Evolving role of uPA/uPAR system in human cancers.

Authors:  Kathleen Dass; Aamir Ahmad; Asfar S Azmi; Sarah H Sarkar; Fazlul H Sarkar
Journal:  Cancer Treat Rev       Date:  2007-12-26       Impact factor: 12.111

Review 8.  The urokinase plasminogen activator system in breast cancer invasion and metastasis.

Authors:  Linlin Tang; Xiuzhen Han
Journal:  Biomed Pharmacother       Date:  2012-11-15       Impact factor: 6.529

Review 9.  Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.

Authors:  Peter F M Choong; Anne P W Nadesapillai
Journal:  Clin Orthop Relat Res       Date:  2003-10       Impact factor: 4.176

10.  Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis.

Authors:  S Nozaki; Y Endo; S Kawashiri; K Nakagawa; E Yamamoto; Y Yonemura; T Sasaki
Journal:  Oral Oncol       Date:  1998-01       Impact factor: 5.337

View more
  1 in total

1.  Hypermethylation of the Promoter Region of miR-23 Enhances the Metastasis and Proliferation of Multiple Myeloma Cells via the Aberrant Expression of uPA.

Authors:  Qijie Ran; Dehong Xu; Qi Wang; Dongsheng Wang
Journal:  Front Oncol       Date:  2022-05-30       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.